Gilead Sciences, Inc.

(NASDAQ Global Select)
Back to all articles
Somewhat Bullish +42

Gilead Sciences (GILD) Stock Could Be 3.6% Undervalued After FDA Filing And Phase 3 HIV Data - simplywall.st

AI-generated analysis

πŸ“ˆ FDA accepted supplemental filing for Yeztugo, a once-weekly oral tablet for HIV prevention.

βœ… Positive Phase 3 data released for a separate once-weekly HIV treatment regimen.

πŸ’° Current share price is $123.76 with a fair value estimate of $128.38 suggesting potential undervaluation.

πŸ“‰ Short-term stock performance shows declines: -7.89% over 30 days and -10.39% over 90 days.

πŸ“ˆ Long-term momentum remains strong with a 1-year total shareholder return of 19.58%.

πŸš€ Company transitioning from single-franchise HIV model to multi-platform biopharma.

πŸ’Š Deep pipeline includes high-probability growth drivers in oncology and long-acting HIV prevention.

⚠️ Near-term earnings face headwinds due to significant acquisition spending.

πŸ“Š Stock trades at 16.7x P/E, slightly above the US biotech average of 16.5x.

🎯 Analysts note a large gap between current price and intrinsic estimates for some programs.

Bullish Signals
  • FDA acceptance of Yeztugo filing and positive Phase 3 data for another HIV regimen validate the company's core therapeutic areas.
  • Strong long-term shareholder returns of 19.58% (1-year) and 119.41% (5-year) indicate sustained investor confidence despite recent volatility.
  • Strategic pivot to a multi-platform biopharma model with deep pipelines in oncology and HIV prevention offers diversified growth opportunities.
  • Valuation gap exists between current price ($123.76) and estimated fair value ($128.38), suggesting potential upside if market re-rates the stock.
Risk Factors
  • Recent share price performance is weak, with a 90-day decline of 10.39% indicating short-term investor skepticism.
  • Near-term earnings are pressured by significant acquisition spending which impacts current profitability metrics.
  • Stock trades at a P/E of 16.7x, which is higher than the sector average of 16.5x, potentially limiting immediate multiple expansion.
Full Analysis
Gilead Sciences (GILD) is receiving positive attention following the FDA's acceptance of a supplemental filing for Yeztugo, a once-weekly oral tablet for HIV prevention. Concurrently, the company reported positive Phase 3 data for a separate once-weekly HIV treatment regimen, reinforcing its pipeline strength in long-acting therapies. At a current share price of $123.76, Gilead has experienced short-term declines with a 30-day return of -7.89% and a 90-day return of -10.39%. However, longer-term momentum remains intact, evidenced by a 1-year total shareholder return of 19.58% and a 5-year return of 119.41%. Analysts suggest the stock may be undervalued with a fair value estimate of $128.38. The company is strategically transitioning from a single-franchise HIV business into a multi-platform biopharma with significant growth drivers in oncology and long-acting HIV prevention. While near-term earnings face headwinds from acquisition spending, the firm possesses one of the deepest pipelines in large-cap biotech, positioning it for a catalyst-rich period where new launches could reshape its earnings mix. Valuation metrics present a mixed picture; Gilead trades at a P/E ratio of 16.7x, which is slightly above the US biotech average of 16.5x but below a calculated fair ratio of 31x. This discrepancy suggests potential upside if the market re-rates the stock to reflect its broader portfolio and growth prospects, though risks from acquisition-related earnings hits and regulatory setbacks remain.